Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nipro Corporation (8086.T)
Osaka, JP
Nipro Corporation, along with its affiliated companies, operates across three primary business divisions: medical devices, pharmaceuticals, and pharmaceutical packaging. The company's Medical Device sector is dedicated to the development, production, and distribution of an extensive selection of disposable medical products. These offerings encompass specialized items for renal treatment, interventional procedures and anesthesia, injection and infusion therapies, dialysis, cardiopulmonary support, diabetes management, and cell culture applications. This division also markets products associated with artificial organs, as well as generic and kit-based medical supplies. Within its Pharmaceutical division, Nipro delivers innovative pharmaceutical combination products, such as dual chamber bags, pre-filled syringes, and half-type kits. It further extends its services through contract manufacturing for orally administered medications, injectable solutions, and topical preparations. The Pharma Packaging segment is focused on providing a comprehensive array of glass packaging solutions. This includes vials, ampoules, syringes, cartridges, and glass tubes. Additionally, this division manufactures glass forming machinery, glass bulbs for vacuum flasks, and various other essential pharmaceutical packaging components, such as rubber stoppers. An 'Other' business activity involves the provision of thermostable enzymes, which are vital for clinical chemistry applications. Nipro also offers business management services. Established in Osaka, Japan, in 1947, Nipro Corporation now serves a wide international customer base, spanning Japan, the Americas, Europe, and other regions across Asia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +11.67% | +9.76% | -0.21% | +7.41% | +8.44% | +9.46% | +19.93% | +62.61% | +23.65% | +38.46% | +283.76% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+2.5% Q1'26: +4.8% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+164.1% ★ Q1'26: -114.8% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%-2.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+5.7% Q1'26: +6.3% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+2.6% Q1'26: +3.0% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.0% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×6.30× Q1'26: 5.85× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 5 Rev. Ana. 5 EPS Ana. |
Mar 2027 3 Rev. Ana. 3 EPS Ana. |
Mar 2028 5 Rev. Ana. 4 EPS Ana. |
Mar 2029 2 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
325.08B
est: 328.00B (-0.9%)
|
366.65B
est: 366.00B (+0.2%)
|
359.70B
est: 361.85B (-0.6%)
|
395.40B
est: 394.60B (+0.2%)
|
426.40B
est: 432.51B (-1.4%)
|
442.52B
est: 448.95B (-1.4%)
|
455.56B
est: 459.98B (-1.0%)
|
494.79B
est: 490.82B (+0.8%)
|
545.20B
est: 550.23B (-0.9%)
|
586.79B
est: 598.58B (-2.0%)
|
644.59B
est: 636.24B (+1.3%)
|
658.83B
651.68B – 669.50B
+3.6% YoY
|
696.66B
677.92B – 715.68B
+5.7% YoY
|
730.14B
729.86B – 730.43B
+4.8% YoY
|
748.78B
728.63B – 769.22B
+2.6% YoY
|
755.23B
734.92B – 775.85B
+0.9% YoY
|
| EBITDA |
49.63B
est: 47.17B (+5.2%)
|
58.92B
est: 52.64B (+11.9%)
|
62.84B
est: 52.04B (+20.7%)
|
62.99B
est: 56.75B (+11.0%)
|
62.45B
est: 62.20B (+0.4%)
|
68.25B
est: 64.57B (+5.7%)
|
70.26B
est: 66.16B (+6.2%)
|
70.05B
est: 70.59B (-0.8%)
|
66.47B
est: 79.14B (-16.0%)
|
81.21B
est: 83.71B (-3.0%)
|
92.25B
est: 88.97B (+3.7%)
|
92.13B
91.13B – 93.62B
+3.6% YoY
|
97.42B
94.80B – 100.08B
+5.7% YoY
|
102.11B
102.07B – 102.15B
+4.8% YoY
|
104.71B
101.89B – 107.57B
+2.6% YoY
|
105.61B
102.77B – 108.50B
+0.9% YoY
|
| EBIT |
16.57B
est: 15.79B (+5.0%)
|
25.08B
est: 17.62B (+42.4%)
|
28.80B
est: 17.42B (+65.4%)
|
27.00B
est: 18.99B (+42.1%)
|
23.83B
est: 20.82B (+14.5%)
|
26.42B
est: 21.61B (+22.3%)
|
27.63B
est: 22.14B (+24.8%)
|
23.88B
est: 23.63B (+1.1%)
|
17.73B
est: 26.48B (-33.1%)
|
22.34B
est: 26.43B (-15.5%)
|
26.60B
est: 28.09B (-5.3%)
|
29.09B
28.77B – 29.56B
+3.6% YoY
|
30.76B
29.93B – 31.60B
+5.7% YoY
|
32.24B
32.23B – 32.25B
+4.8% YoY
|
33.06B
32.17B – 33.96B
+2.6% YoY
|
33.35B
32.45B – 34.26B
+0.9% YoY
|
| Net Income |
12.47B
est: 15.52B (-19.7%)
|
19.72B
est: 16.27B (+21.2%)
|
11.35B
est: 18.85B (-39.8%)
|
11.83B
est: 22.22B (-46.8%)
|
12.14B
est: 17.32B (-29.9%)
|
-12.28B
est: 3.82B (-421.4%)
|
14.21B
est: 15.31B (-7.2%)
|
13.46B
est: 16.39B (-17.9%)
|
4.58B
est: 12.88B (-64.5%)
|
11.11B
est: 10.88B (+2.1%)
|
5.11B
est: 18.43B (-72.3%)
|
14.65B
14.01B – 18.95B
-20.5% YoY
|
14.07B
12.40B – 17.81B
-3.9% YoY
|
18.37B
14.73B – 26.07B
+30.6% YoY
|
18.01B
17.37B – 18.64B
-2.0% YoY
|
19.62B
18.94B – 20.32B
+9.0% YoY
|
| SGA |
74.34B
est: 74.92B (-0.8%)
|
80.52B
est: 83.59B (-3.7%)
|
74.78B
est: 82.65B (-9.5%)
|
85.68B
est: 90.13B (-4.9%)
|
91.69B
est: 98.79B (-7.2%)
|
105.20B
est: 102.54B (+2.6%)
|
109.11B
est: 105.06B (+3.9%)
|
109.22B
est: 112.10B (-2.6%)
|
128.50B
est: 125.67B (+2.3%)
|
130.80B
est: 137.01B (-4.5%)
|
145.39B
est: 145.63B (-0.2%)
|
150.80B
149.16B – 153.24B
+3.6% YoY
|
159.45B
155.16B – 163.81B
+5.7% YoY
|
167.12B
167.05B – 167.18B
+4.8% YoY
|
171.38B
166.77B – 176.06B
+2.6% YoY
|
172.86B
168.21B – 177.58B
+0.9% YoY
|
| EPS |
80.95
est: 84.34 (-4.0%)
|
116.22
est: 88.40 (+31.5%)
|
67.57
est: 102.39 (-34.0%)
|
71.14
est: 120.72 (-41.1%)
|
73.68
est: 94.11 (-21.7%)
|
-75.30
est: 20.76 (-462.7%)
|
87.12
est: 83.19 (+4.7%)
|
82.50
est: 89.05 (-7.4%)
|
28.04
est: 70.54 (-60.3%)
|
68.11
est: 59.08 (+15.3%)
|
31.35
est: 100.10 (-68.7%)
|
90.58
76.11 – 102.94
-9.5% YoY
|
78.46
67.36 – 96.76
-13.4% YoY
|
106.09
80.04 – 141.63
+35.2% YoY
|
97.79
94.37 – 101.26
-7.8% YoY
|
106.60
102.87 – 110.38
+9.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 1/5 | 3/5 | 3/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 1/5 | 3/5 | 3/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Akihiko Yamabe | Mang. of Accounting Department - Corporation Planning Division | — | male |
| Goichi Miyazumi | Director & GM of International Business Division | — | male |
| Hideto Nakamura | GM of General Affairs, HR Division & Governance and Director | — | male |
| Kaname Sadahiro | GM of Intn. Business, Domestic Business Division Product Dev., Technical Sales & Director | — | — |
| Kenichi Nishida | MD, Head of Pharmaceutical Business Division and Pharmaceutical Production & Director | — | male |
| Kimihito Minoura | MD, Head of Regenerative Medicine and Business Promotion, Business Management & Director | — | male |
| Takehito Yogo | Senior MD, GM of Corporate Planning Div, Manager of Corporate Planning Dept, CSO & Director | — | male |
| Tsuyoshi Yamazaki | Executive MD of PharmaPackaging, Head of International Bus. & Director | — | male |
| Yasushi Oyama | MD, Head of Vascular Business Division & Director | — | male |
| Yoshihiko Sano | Chairman of Board & President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 8086.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
